$TRYPF News
Last published 3y ago
- 3y agoTRYPFTryp Therapeutics to Present at Biotech Showcase on Monday, January 9, 2023GlobeNewswireKELOWNA, British Columbia, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE:TRYP) (OTCQB:TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active
- 3y agoTRYPFTryp Therapeutics Announces Fiscal Year 2022 Financial Results and Reports Corporate HighlightsGlobeNewswireKELOWNA, British Columbia, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE:TRYP) (OTCQB:TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active
- 3y agoTRYPFTryp Therapeutics to Webcast Live at VirtualInvestorConferences.com on Thursday, December 15GlobeNewswireKELOWNA, British Columbia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE:TRYP) (OTCQB:TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active
- 4y agoTRYPFTryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain in a Rodent Model with Psilocybin and Intravenous Psilocybin Alters Brain Network Dynamics in Rats at the 2022 Society for Neuroscience ConferenceGlobeNewswireKELOWNA, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE:TRYP) (OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing
- 4y agoTRYPFTryp Therapeutics Announces Publication of International PCT Patent Application for the Intravenous Administration of Psilocin and PsilocybinGlobeNewswireEnables Potentially Scalable Model For The Broad Roll-Out of Psychedelic Treatments Company Will Host Investor Update Tuesday, October 4th KELOWNA, British Columbia, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE:TRYP
- 4y agoTRYPFTryp Therapeutics Strengthens Intellectual Property Portfolio with Provisional Patent Applications for Fibromyalgia Treatment and for Crystalline Forms of TRP-8803GlobeNewswireKELOWNA, British Columbia, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE:TRYP) (OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet me
- 4y agoTRYPFTryp Therapeutics Retains IMS Investor RelationsGlobeNewswireKELOWNA, British Columbia, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE:TRYP) (OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet me
- 4y agoTRYPFTryp Therapeutics Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder TreatmentPR NewswireBiotech Company Strengthens Strategic Intellectual Property Protection of Targeted Indication SAN DIEGO, June 29, 2022 /PRNewswire/ -- Tryp Therapeutics, Inc. (CSE:TRYP) (OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company f
- 4y agoTRYPFTryp Therapeutics Appoints New Chief Operating OfficerPR NewswireSid Taubenfeld with Extensive Experience in the Financial Markets and as a Biotech Executive Joins Tryp as Company Prepares to Expand Patient Access to Psilocybin-Based Treatments SAN DIEGO, June 23, 2022 /PRNewswire/ -- Tryp Therapeutics, Inc. (CSE:T
- 4y agoTRYPFTRYP THERAPEUTICS ANNOUNCES RESULTS OF FIRST PATIENT DOSED IN ITS PHASE II CLINICAL TRIAL FOR THE TREATMENT OF BINGE EATING DISORDERPR NewswireInitial data readout supports the potential effectiveness of psilocybin and psilocybin-related compounds for the treatment of Binge Eating Disorder SAN DIEGO, June 9, 2022 /PRNewswire/ -- Tryp Therapeutics, Inc. (CSE:TRYP) (OTCQB:TRYPF) ("Tryp" or th
- 4y agoTRYPFTryp Therapeutics Strengthens Board of Directors with Appointment of Chris Ntoumenopoulos as Independent DirectorPR NewswireIndustry leader Chris Ntoumenopoulos to support biotech Company's mission to advance the delivery of psychedelic medicines SAN DIEGO, May 25, 2022 /PRNewswire/ -- Tryp Therapeutics, Inc. (CSE:TRYP) (OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical
- 4y agoTRYPFTRYP THERAPEUTICS DOSES FIRST PATIENT IN PHASE II PSILOCYBIN-ASSISTED THERAPY CLINICAL TRIALPR NewswirePhase II trial to determine efficacy of psilocybin in combination with psychotherapy for potential treatment of Binge Eating Disorder SAN DIEGO, April 28, 2022 /PRNewswire/ -- Tryp Therapeutics, Inc. (CSE:TRYP) (OTCQB:TRYPF) ("Tryp" or the "Company"),
- 4y agoTRYPFTryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of FloridaPR NewswirePhase 2 study is the first approved by the FDA and DEA to test psychedelic therapies in the area of binge eating disorders SAN DIEGO, March 23, 2022 /PRNewswire/ -- Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF) ("Tryp" or the "Company"), a pharmaceutic
- 4y agoTRYPFTryp Therapeutics Announces Q1 2022 Financial ResultsPR NewswireSAN DIEGO, Jan. 28, 2022 /PRNewswire/ -- Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today its interim f
- 4y agoTRYPFTryp Therapeutics to Participate in Healthcare Conferences in January 2022PR NewswireSAN DIEGO, Jan. 5, 2022 /PRNewswire/ -- Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it
- 4y agoTRYPFTryp Therapeutics Announces Advancement of Phase 2a Clinical Trial in Binge Eating DisorderPR NewswireSAN DIEGO, Dec. 23, 2021 /PRNewswire/ -- Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the receipt
- 4y agoTRYPFTryp Therapeutics Announces Fiscal Year 2021 Financial Results and Reports on Corporate HighlightsPR NewswireSAN DIEGO, Dec. 22, 2021 /PRNewswire/ -- Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the filing o
- 4y agoTRYPFTryp Therapeutics to Present at the H.C. Wainwright Psychedelics Conference on December 6, 2021PR NewswireSAN DIEGO, Dec. 3, 2021 /PRNewswire/ -- Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF) ("Tryp or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it will pre
- 4y agoTRYPFTryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2a Study in FibromyalgiaPR NewswireSAN DIEGO, Dec. 2, 2021 /PRNewswire/ -- Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has re
- 4y agoTRYPFTryp Therapeutics Provides Update on Clinical Hold for Phase 2a Study for Eating DisordersPR NewswireSAN DIEGO, Nov. 18, 2021 /PRNewswire/ -- Tryp Therapeutics (CSE:TRYP, OTCQB:TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has re
- 5y agoTRYPFGeneTether Announces Organizational Changes Designed to Support Continued GrowthGlobeNewswireBERKELEY, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- GeneTether Inc. ("GeneTether" or the "Company"), a Bay Area biotech company focused on developing technologies to increase the correction efficiency of targeted genome editing technologies, today ann
- 5y agoAWKNFBETRFBMBIFCYBN+16KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand ViewingPR NewswireNEW YORK, Oct. 18, 2021 /PRNewswire/ -- Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing.
- 5y agoAWKNFBETRFBMBIFCYBN+13KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14thPR NewswireNEW YORK, Oct. 11, 2021 /PRNewswire/ -- Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference. Individual investors, institutional inves
- 5y agoTRYPFTryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Next Wave of Psychedelic Drug DevelopmentGlobeNewswireNEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Tryp Therapeutics Inc. (CSE:TRYP) (OTCQB:TRYPF) announces the availability of a broadcast titled, "Investors Turning to Psychedelic Market as Renaissance Continues into New Wave of Dise
- 5y agoFTRPFMYCOFSEELTRYPFPsychedelics Called the 'Next Frontier' for Investors, Also Offer Promising TreatmentsPR NewswireNEW YORK, Sept. 29, 2021 /PRNewswire/ -- The fact that psychedelics is a nascent industry doesn't seem to be discouraging savvy investors exploring the opportunities. A recent Fortune article noted that "despite being an industry in its early stages, the
- 5y agoTRYPFTryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Redefining Standards, Refining PsychiatryGlobeNewswireNEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Tryp Therapeutics Inc. (CSE:TRYP) (OTCQB:TRYPF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetw
- 5y agoATAICMPSCYBNMNMD+1Investors Turning to Psychedelic Market as Renaissance Continues into New Wave of DiseasesPR NewswireNEW YORK, Sept. 27, 2021 /PRNewswire/ -- The emergence of psychedelic therapies as a popular investment a few years ago was mostly underscored by investors that rode the cannabis wave seeing a brand-new opportunity with drugs such as psilocybin, LSD, MD
- 5y agoCMPSMNMDPHRRFTRYPFSenate Bill Decriminalizing Psychedelics Could Help Reverse Some 'War on Drugs' ImpactsPR NewswireNEW YORK, Sept. 22, 2021 /PRNewswire/ -- The global need for effective mental health treatment has led to the growing push for the legalization of psychedelic therapies, pushing the market into the mainstream. Last week, Michigan Senator Jeff Irwin intro
- 5y agoTRYPFInvestorBrandNetwork Announces The Dealmaker Show Interview with Tryp Therapeutics Inc. CEO Greg McKeeGlobeNewswireLOS ANGELES, Aug. 03, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – InvestorBrandNetwork ("IBN"), a multifaceted financial news and publishing company for private and public entities, today announces that Greg McKee, Chairman & CEO of Tryp Therapeutics
- 5y agoTRYPFTryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Exploring Psilocybin Treatments in Underserved IndicationsGlobeNewswireNEW YORK, July 30, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Tryp Therapeutics Inc. (CSE:TRYP) (OTCQB:TRYPF) announces the availability of a broadcast titled, "Psychedelics — Not Just for Mental Health Anymore." To hear the AudioPressRelease,
- 5y agoFTRPFSEELTRYPFCompanies Smashing the Psychedelic CeilingPR NewswireNEW YORK, July 29, 2021 /PRNewswire/ -- It's early on in a burgeoning market, but there is certainly reason to be optimistic about the future of psychedelic medicines as a promising treatment for a broad spectrum of diseases and conditions. In fact, some
- 5y agoTRYPFTryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Developing Evidence-Based Innovation Where Drugs Are LackingGlobeNewswireNEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Tryp Therapeutics Inc. (CSE:TRYP) (OTCQB:TRYPF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwo
- 5y agoATAICLXPFCMPSMNMD+1Psychedelics -- Not Just for Mental Health AnymorePR NewswireNEW YORK, July 27, 2021 /PRNewswire/ -- In July 2012, Congress created what is known as Breakthrough Therapy designation, a distinction that affords biotechnology and pharmaceutical companies an expedited review process for experimental drugs that may ha
- 5y agoLKYSFMNMDMYCOFSEEL+1Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental IllnessPR NewswireNEW YORK, July 21, 2021 /PRNewswire/ -- The early 1970s saw psychedelics and psilocybin products made illegal in the US in the war on drugs. Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of ch
- 5y agoTRYPFTryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Differentiated by Clinical Trials, World-Class ManagementGlobeNewswireNEW YORK, July 01, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Tryp Therapeutics Inc. (CSE:TRYP) (OTCQB:TRYPF) announces the availability of a broadcast titled, "GW Pharma Sells for Bilions; Psychedelic Company Following Similar Path." To hear th
- 5y agoTRYPFTryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Charting Its Own Course in Psychedelic SpaceGlobeNewswireNEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Tryp Therapeutics Inc. (CSE:TRYP) (OTCQB:TRYPF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwo
- 5y agoATAICMPSJAZZMNMD+1GW Pharma Sells for Billions; Psychedelic Company Following Similar PathPR NewswireNEW YORK, June 29, 2021 /PRNewswire/ -- In May 2013, GW Pharma listed on Nasdaq, selling 3.5 million shares at $8.90 each to investors betting that GW was charting a profitable course as a biotech developing new drugs from cannabis-derived compounds. Le
- 5y agoTRYPFInvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast featuring Tryp Therapeutics Inc. Chairman and CEO Greg McKeeGlobeNewswireLOS ANGELES, June 17, 2021 (GLOBE NEWSWIRE) -- (via InvestorWire) InvestorBrandNetwork ("IBN"), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the la
- 5y agoTRYPFTryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Brings Best-in-Class Team to Psychedelics DevelopmentGlobeNewswireNEW YORK, May 21, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Tryp Therapeutics Inc. (CSE:TRYP) (OTCQB:TRYPF) announces the availability of a broadcast titled, "Wall Street Unicorns in Process of Changing the Healthcare Landscape." To hear the Au
- 5y agoGWPHJAZZSEELTRYPFNatural Drug Treatments Offer Promise, Potential as Savvy Drug Developers Recognize True OpportunitiesPR NewswireNEW YORK, May 20, 2021 /PRNewswire/ -- Before government legislation brought the world of psychedelic drug compounds to a halt, promising research was being done in the space. As researchers and scientists took closer looks at substances such as psilocy
- 5y agoTRYPFTryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Bringing Diversified Pipeline to Psychedelic RevivalGlobeNewswireNEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Tryp Therapeutics Inc. (CSE:TRYP) (OTCQB:TRYPF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwor
- 5y agoCLXPFCMPSFTRPFMNMD+1Wall Street Unicorns in Process of Changing the Healthcare LandscapePR NewswireNEW YORK, May 18, 2021 /PRNewswire/ -- Before 1970, promising research was being conducted on the potential therapeutic effects of a broad category of psychedelic drug compounds, including substances such as psilocybin, DMT (dimethyltryptamine), LSD (lys
- 5y agoCLXPFCMPSLLYMRK+1Psychedelics Move to The Forefront of Innovative Research as the FDA Approves Large-Scale TestingPR NewswireNEW YORK, May 13, 2021 /PRNewswire/ -- Psychedelics are quietly being used in clinical settings on small numbers of patients, but they are moving quickly toward medical approval. The FDA recently approved large-scale human trials to determine whether MD
- 5y agoAMGNBMYJNJPFE+1A Growing Market For Rare Disease Treatments Opens Up New OpportunitiesPR NewswireNEW YORK, April 28, 2021 /PRNewswire/ -- There are currently thousands of health conditions that affect people's lives for which few or no effective treatment options currently exist. Each one of these conditions is an unaddressed market need in addition